Show simple item record

Removing race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principles

dc.contributor.authorPai, Manjunath P.
dc.contributor.authorSitaruno, Sirima
dc.contributor.authorAbdelnabi, Mohamed
dc.date.accessioned2023-03-03T21:11:30Z
dc.date.available2024-02-03 16:11:28en
dc.date.available2023-03-03T21:11:30Z
dc.date.issued2023-01
dc.identifier.citationPai, Manjunath P.; Sitaruno, Sirima; Abdelnabi, Mohamed (2023). "Removing race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principles." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy (1): 35-42.
dc.identifier.issn0277-0008
dc.identifier.issn1875-9114
dc.identifier.urihttps://hdl.handle.net/2027.42/175952
dc.description.abstractStudy ObjectiveThe use of race in medicine can contribute to health inequity. Updated equations for estimated glomerular filtration rate (eGFR) without race have been published. Likewise, de-indexation of eGFR to body surface area (BSA) has been recommended by regulatory guidance for drug dosing in renal impairment. Clinical data justifying these recommendations for drug dosing are sparse. We examined the gain or loss of precision in drug dosing with estimated creatinine clearance (eCLcr) and eGFR using serum creatinine (eGFRcr) with and without race and BSA indexation by evaluating the population pharmacokinetics of the aminoglycosides as a classic drug class to probe kidney function.DesignMedical records from adult patients treated with gentamicin or tobramycin over a 13-year period were queried. Population pharmacokinetic analyses were performed using a 1-compartment base structural model. Models compared body size descriptors as covariates of the volume of distribution (V). Estimated creatinine clearance and eGFRcr using multiple contemporary equations with and without BSA indexation were tested as covariates of clearance (CL).Main ResultsThe final data set included 2968 patients treated with either gentamicin (20.2%) or tobramycin (79.8%). Patients self-identified as Caucasian (82%), African-American (10%), or other. The median [5th, 95th percentile] weight and BSA were 80.5 [49.4, 136] kg and 1.94 [1.48, 2.56] m2, respectively. Models of eCLcr and eGFRcr without indexation to BSA had a better model fit than eGFRcr indexed to BSA for aminoglycoside CL. The 2021 Chronic Kidney Disease Epidemiology collaboration (CKD-EPI) eGFRcr equation (no race, no BSA indexation) provided a comparable model fit to the 2009 CKD-EPI eGFRcr equation (with race, no BSA indexation) for aminoglycoside CL.ConclusionsRace is not a relevant covariate of aminoglycoside CL. The 2021 CKD-EPI eGFR equation without race and BSA indexation is a better method for gentamicin and tobramycin CL estimation. Confirmation of these results for other drugs can support the harmonization of dosing by kidney function.
dc.publisherWiley Periodicals, Inc.
dc.publisherSpringer-Verlag
dc.subject.otherrace
dc.subject.otherregulatory
dc.subject.otherstructural racism
dc.subject.otherAfrican
dc.subject.otherblack
dc.subject.otherclearance
dc.subject.otherdrug development
dc.subject.otherdrug dosing
dc.subject.otherkidney
dc.subject.otherprecision medicine
dc.titleRemoving race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principles
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175952/1/phar2746_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175952/2/phar2746-sup-0001-Supplementary_File.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175952/3/phar2746.pdf
dc.identifier.doi10.1002/phar.2746
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
dc.identifier.citedreferenceBurnham KP, Anderson DR. Model Selection and Inference: A Practical Information-Theoretic Approach. 2nd ed. Springer-Verlag; 2002.
dc.identifier.citedreferenceDelgado C, Baweja M, Burrows NR, et al. Reassessing the inclusion of race in diagnosing kidney diseases: an interim report from the NKF-ASN task force. Am J Kidney Dis. 2021; 1: 103 - 115.
dc.identifier.citedreferenceInker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021; 19: 1737 - 1749.
dc.identifier.citedreferenceCasal MA, Ivy SP, Beumer JH, Nolin TD. Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants. Lancet Oncol. 2021; 9: 1333 - 1340.
dc.identifier.citedreferenceDelanaye P, Masson I, Maillard N, Pottel H, Mariat C. The new 2021 CKD-EPI equation without race in a European cohort of renal transplanted patients. Transplantation. 2022. doi: 10.1097/TP.0000000000004234. Epub ahead of print.
dc.identifier.citedreferenceLevey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604 - 612.
dc.identifier.citedreferenceJeong TD, Lee W, Yun YM, Chun S, Song J, Min WK. Development and validation of the Korean version of CKD-EPI equation to estimate glomerular filtration rate. Clin Biochem. 2016; 9: 713 - 719.
dc.identifier.citedreferenceTeo BW, Xu H, Wang D, et al. GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis. 2011; 1: 56 - 63.
dc.identifier.citedreferenceMatsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 6: 982 - 992.
dc.identifier.citedreferenceZuo L, Ma YC, Zhou YH, Wang M, Xu GB, Wang HY. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis. 2005; 3: 463 - 472.
dc.identifier.citedreferenceDelanaye P, Krzesinski JM. Indexing of renal function parameters by body surface area: intelligence or folly? Nephron Clin Pract. 2011; 4: c289 - c292.
dc.identifier.citedreferenceHeaf JG. The origin of the 1 × 73-m 2 body surface area normalization: problems and implications. Clin Physiol Funct Imaging. 2007; 3: 135 - 137.
dc.identifier.citedreferencePai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012; 9: 856 - 868.
dc.identifier.citedreferencePetersen R, Pan L, Blanck HM. Racial and ethnic disparities in adult obesity in the United States: CDC’s tracking to inform state and local action. Prev Chronic Dis. 2019; 16: E46.
dc.identifier.citedreferenceUS Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation Research. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function –Study Design, Data Analysis, and Impact on Dosing. 2020.
dc.identifier.citedreferenceTrang M, Seroogy JD, Van Wart SA, et al. Population pharmacokinetic analyses for plazomicin using pooled data from phase 1, 2, and 3 clinical studies. Antimicrob Agents Chemother. 2019; 63: e02329 - e02318.
dc.identifier.citedreferenceCockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 1: 31 - 41.
dc.identifier.citedreferenceDuffull SB, Wright DF, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. Br J Clin Pharmacol. 2011; 6: 807 - 814.
dc.identifier.citedreferencePai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother. 2011; 9: 4006 - 4011.
dc.identifier.citedreferenceDuong A, Simard C, Wang YL, Williamson D, Marsot A. Aminoglycosides in the intensive care unit: what is new in population PK modeling? Antibiotics. 2021; 10: 507.
dc.identifier.citedreferenceEneanya ND, Boulware LE, Tsai J, et al. Health inequities and the inappropriate use of race in nephrology. Nat Rev Nephrol. 2022; 2: 84 - 94.
dc.identifier.citedreferenceSilva AM, Shen W, Heo M, et al. Ethnicity-related skeletal muscle differences across the lifespan. Am J Hum Biol. 2010; 1: 76 - 82.
dc.identifier.citedreferencePeralta CA, Risch N, Lin F, et al. The Association of African Ancestry and elevated creatinine in the coronary artery risk development in young adults (CARDIA) study. Am J Nephrol. 2010; 3: 202 - 208.
dc.identifier.citedreferenceJafar TH, Schmid CH, Levey AS. Serum creatinine as marker of kidney function in south Asians: a study of reduced GFR in adults in Pakistan. J Am Soc Nephrol. 2005; 5: 1413 - 1419.
dc.identifier.citedreferenceVespa JAD, Medina L. Demographic Turning Points for the United States: Population Projections for 2020 to 2060. Current Population Reports, US Census Bureau; 2018: P25 - P1144.
dc.identifier.citedreferenceBamfo NO, Hosey-Cojocari C, Benet LZ, Remsberg CM. Examination of urinary excretion of unchanged drug in humans and preclinical animal models: increasing the predictability of poor metabolism in humans. Pharm Res. 2021; 7: 1139 - 1156.
dc.identifier.citedreferenceLal R, Sukbuntherng J, Luo W, Tovera J, Lassauzet ML, Cundy KC. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. J Clin Pharmacol. 2013; 1: 29 - 40.
dc.identifier.citedreferenceCrass RL, Pai MP. Estimating renal function in drug development: time to take the fork in the road. J Clin Pharmacol. 2019; 2: 159 - 167.
dc.identifier.citedreferenceMohottige D, Boulware LE, Ford CL, Jones C, Norris KC. Use of race in kidney research and medicine: concepts, principles, and practice. Clin J Am Soc Nephrol. 2022; 2: 314 - 322.
dc.identifier.citedreferenceAklilu A, Delgado C. The removal of race from kidney function estimation: key points for primary providers. J Natl Med Assoc. 2022; 114: S25 - S33.
dc.identifier.citedreferencePai MP. Antimicrobial dosing in specific populations and novel clinical methodologies: kidney function. Clin Pharmacol Ther. 2021; 4: 952 - 957.
dc.identifier.citedreferenceDelanaye P, Mariat C, Cavalier E, Glassock RJ, Gemenne F, Pottel H. The << race >> correction in estimating glomerular filtration rate: an European point of view. Curr Opin Nephrol Hypertens. 2021; 6: 525 - 530.
dc.identifier.citedreferencePottel H, Hoste L, Delanaye P, Cavalier E, Martens F. Demystifying ethnic/sex differences in kidney function: is the difference in (estimating) glomerular filtration rate or in serum creatinine concentration? Clin Chim Acta. 2012; 413: 1612 - 1617.
dc.identifier.citedreferenceInker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 1: 20 - 29.
dc.identifier.citedreferencePurnell TS, Luo X, Cooper LA, et al. Association of race and ethnicity with live donor kidney transplantation in the United States from 1995 to 2014. JAMA. 2018; 1: 49 - 61.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.